Research article summary (published 30 Aug 2009):

Diabetic neuropathy: therapies on the horizon.

Full Abstract

OBJECTIVES: This is a review of emerging interventions from the recent preclinical and clinical literature that demonstrate the potential for effectiveness in the therapy of diabetic neuropathy (DN). DN is the most common complication of diabetes mellitus and up to 50% of patients with type 1 and type 2 forms have some or other form of neuropathy. The pathology of DN is characterized by progressive nerve fibre loss that gives rise to positive and negative clinical signs and symptoms such as pain, paraesthesiae and loss of sensation. KEY FINDINGS: There are very few drugs available to directly treat DN. Those that are clinically indicated provide symptomatic relief but do not repair or reverse underlying nerve damage. However, some agents are in clinical development that may support adult neurons and direct reparative processes after injury stages. Several disease modifying drugs such as aldose reductase inhibitors and protein kinase C inhibitors are in phase III development. Agents on the horizon include neurotrophic factors, growth factors, gene therapy, immunotherapy, poly(ADP-ribose) polymerase inhibitors and non-immunosuppressive immunophilin ligands. SUMMARY: Progress has been made toward understanding the biochemical mechanisms leading to diabetic neuropathy, and as a result, new treatment modalities are being explored. The pathogenesis, types and approaches for treating DN together with the newer therapeutic interventions on the horizon are discussed.

Author information

Author/s: Mahmood, Danish (D); Singh, Bhulan Kumar (BK); Akhtar, Mohammad (M);

Affiliation: Department of Pharmacology, Hamdard University, Hamdard Nagar, New Delhi 110062, India.

Journal and publication information

Publication Type: Journal Article; Review

Journal: The Journal of pharmacy and pharmacology (J Pharm Pharmacol), published in England. (Language: eng)

Reference: 2009-Sep; vol 61 (issue 9) : pp 1137-45

Dates: Created 2009/08/25; Completed 2009/10/22;

PMID: 19703362, status: MEDLINE (last retrieval date: 10/22/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Animals Antioxidants - therapeutic use Clinical Trials as Topic Diabetic Neuropathies - classification; drug therapy; etiology Enzyme Inhibitors - therapeutic use Gene Therapy

Gene Therapy Humans Immunophilins - therapeutic use Immunotherapy Intercellular Signaling Peptides and Proteins - therapeutic use Models, Biological

Associated Chemicals: Antioxidants (0) ; Enzyme Inhibitors (0) ; Intercellular Signaling Peptides and Proteins (0) ; Immunophilins (EC 5.2.1.8)

Related articles

These are the highest related articles currently in the database:

• The effect of alpha-lipoic acid on the neurovascular reflex arc in patients with diabetic neuropathy assessed by capillary microscopy. 29 Jun 1999
• Report on the conjoint meetings of the Diabetic Neuropathy Study Group of the EASD (NEURODIAB) VII and the 4th Diabetic Neuropathy IDF satellite meeting held in Noordwijkerhout, The Netherlands, July 15-19, 1997. 29 Nov 1997
• Treatment of symptomatic diabetic neuropathy. 30 Dec 2002
• [Polyneuropathy--therapy] 12 Mar 2003
• Diabetic neuropathy. 29 Jun 1998
• Glycation in diabetic neuropathy: characteristics, consequences, causes, and therapeutic options. 30 Dec 2001
• Clinical potential of aldose reductase inhibitors in diabetic neuropathy. 30 Dec 2003
• Treatment of diabetic polyneuropathy with alpha-lipoic acid is evidence based. 30 Dec 2003
• Potent antioxidant improves diabetic nerve damage. 29 Sep 2003
• [Diabetic polyneuropathy. Sequential therapy with alpha-lipoic acid passes the general practice test] 5 Sep 2000

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.